CA2182986A1 - Use of insulin sensitisers for treating renal diseases - Google Patents

Use of insulin sensitisers for treating renal diseases

Info

Publication number
CA2182986A1
CA2182986A1 CA002182986A CA2182986A CA2182986A1 CA 2182986 A1 CA2182986 A1 CA 2182986A1 CA 002182986 A CA002182986 A CA 002182986A CA 2182986 A CA2182986 A CA 2182986A CA 2182986 A1 CA2182986 A1 CA 2182986A1
Authority
CA
Canada
Prior art keywords
formula
insulin sensitiser
group
insulin
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002182986A
Other languages
English (en)
French (fr)
Inventor
Robin Edwin Buckingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9402624A external-priority patent/GB9402624D0/en
Priority claimed from GB9410214A external-priority patent/GB9410214D0/en
Priority claimed from GBGB9426019.7A external-priority patent/GB9426019D0/en
Application filed by Individual filed Critical Individual
Publication of CA2182986A1 publication Critical patent/CA2182986A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002182986A 1994-02-10 1995-02-07 Use of insulin sensitisers for treating renal diseases Abandoned CA2182986A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9402624.2 1994-02-10
GB9402624A GB9402624D0 (en) 1994-02-10 1994-02-10 Novel method
GB9410214A GB9410214D0 (en) 1994-05-21 1994-05-21 Novel method
GB9410214.2 1994-05-21
GBGB9426019.7A GB9426019D0 (en) 1994-12-22 1994-12-22 Novel method
GB9426019.7 1994-12-22

Publications (1)

Publication Number Publication Date
CA2182986A1 true CA2182986A1 (en) 1995-08-17

Family

ID=27267046

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182986A Abandoned CA2182986A1 (en) 1994-02-10 1995-02-07 Use of insulin sensitisers for treating renal diseases

Country Status (11)

Country Link
EP (1) EP0777469A1 (es)
JP (1) JPH09512249A (es)
CN (2) CN1083715C (es)
AP (1) AP553A (es)
AU (1) AU700826B2 (es)
CA (1) CA2182986A1 (es)
IL (1) IL112590A (es)
MX (1) MX9603338A (es)
SG (1) SG47100A1 (es)
TW (1) TW475896B (es)
WO (1) WO1995021608A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5985884A (en) * 1996-07-01 1999-11-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
OA11871A (en) 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
BR0013375A (pt) * 1999-08-17 2002-07-23 Smithkline Beecham Plc Composições farmacêuticas contendo derivados tiazolidinodiona e processo para sua preparação
EP1284291A4 (en) * 2000-05-25 2005-06-08 Yamanouchi Pharma Co Ltd PROMOTER OF HUMAN PGC-1
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
JP2008531707A (ja) 2005-03-03 2008-08-14 スミスクライン ビーチャム コーポレーション 医薬品
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
GB9023584D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05310719A (ja) * 1992-04-28 1993-11-22 Terumo Corp チアゾリジン−２，４−ジオン誘導体

Also Published As

Publication number Publication date
CN1083715C (zh) 2002-05-01
EP0777469A1 (en) 1997-06-11
CN1318372A (zh) 2001-10-24
IL112590A (en) 2002-08-14
WO1995021608A1 (en) 1995-08-17
AP553A (en) 1996-11-06
AP9500717A0 (en) 1995-04-30
SG47100A1 (en) 1998-03-20
JPH09512249A (ja) 1997-12-09
IL112590A0 (en) 1995-06-29
AU1578395A (en) 1995-08-29
MX9603338A (es) 1997-03-29
TW475896B (en) 2002-02-11
CN1145027A (zh) 1997-03-12
AU700826B2 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
CA2182986A1 (en) Use of insulin sensitisers for treating renal diseases
Connor et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase
ES2197213T3 (es) Uso de pramipexol como agente neuroprotector.
US20040053989A1 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
CZ198296A3 (en) Preparations for treating arteriosclerosis and xanthoma
EP0695183B1 (en) Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders
US5424301A (en) Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
JPS63264421A (ja) 高脂質血症治療剤
EP0921798A1 (en) Novel treatment of leptine resistance
AU2018219213A1 (en) Treatment of diabetes and associated metabolic conditions with epigenetic modulators
CA1261272A (en) Dihydropyridine combination product
CN101272805A (zh) 包含PPARγ激动剂的药物组合物
US20030109552A1 (en) Use of insulin sensitisers for treating renal diseases
US20020115699A1 (en) Method for treating renal disease
WO2001052849A1 (fr) Remedes contre le diabete
AU2001261409A1 (en) Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with NS398 or PDTC
HU229425B1 (en) Use of thiazole derivatives for preparing a medicine for protecting mitochondria
CZ32998A3 (cs) Výroba léčiva pro snížení množství exogenního insulinu
US20040266833A1 (en) Novel use of certain insulin sensitizers or ppar-gamma agonists
CA2417883A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
WO1999012548A1 (en) Treatment of inflammatory conditions
NZ506200A (en) Use of a leptine sensitiser in combination with leptin to treat leptine resistance conditions (e.g. obesity)
HU224436B1 (hu) Az 5-[4-{2-[N-metil-N-(2-piridil)-amino]-etoxi}-benzil]-2,4-dioxotiazolidin alkalmazása vesebetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
AU7217000A (en) Novel treatment of leptin resistance
WO2000047209A1 (en) Methods of modulating uric acid levels

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued